Skip to main content
Erschienen in: Strahlentherapie und Onkologie 1/2023

07.10.2022 | Original Article

Knockdown of circ-ADAM9 inhibits malignant phenotype and enhances radiosensitivity in breast cancer cells via acting as a sponge for miR-383-5p

verfasst von: Penghui Song, Jianjun Wu, Jianbing Chen, Fang Wang, Jingmei Chen, Guanyu Wang

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Circular RNA (circRNA) has been proven to play a critical role in breast cancer progression. Therefore, this study was designed to clarify the role and underlying molecular mechanisms of circ-disintegrin and metalloproteinase 9 (circ-ADAM9) in breast cancer.

Methods

A quantitative real-time polymerase chain reaction (RT-qPCR) was conducted to assess the expression levels of circ-ADAM9, microRNA-383-5p (miR-383-5p), and profilin 2 (PFN2). Cellular growth curves of breast cancer cells were determined by colony-forming assay. Cell viability and apoptosis were measured by MTT and flow cytometry, respectively. The protein expression level was analyzed by western blot. Cell migration and invasion were evaluated by wound healing and Transwell assays. A xenograft experiment was established to clarify the functional role of circ-ADAM9 inhibition in vivo. The interactions among circ-ADAM9, miR-383-5p, and PFN2 were analyzed by dual-luciferase reporter, RNA immunoprecipitation (RIP), and RNA pull-down assays.

Results

We found that circ-ADAM9 was upregulated in breast cancer tissues and cells compared to controls. Inhibition of circ-ADAM9 expression impaired proliferation, migration, and invasion, but increased radiosensitivity and apoptosis in breast cancer cells; besides, radiotherapy combined with circ-ADAM9 inhibition showed significant inhibitory effects on tumor growth. The functional effects of circ-ADAM9 were related to miR-383-5p, a target of circ-ADAM9. Overexpression of miR-383-5p-mediated malignant behaviors and radiosensitivity of breast cancer cells were dependent on PFN2.

Conclusion

Circ-ADAM9 was found to participate in breast cancer progression through targeting the miR-383-5p/PFN2 axis.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Anastasiadi Z et al (2017) Breast cancer in young women: an overview. Updates Surg 69(3):313–317CrossRef Anastasiadi Z et al (2017) Breast cancer in young women: an overview. Updates Surg 69(3):313–317CrossRef
3.
Zurück zum Zitat Fahad Ullah M (2019) Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 1152:51–64CrossRef Fahad Ullah M (2019) Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 1152:51–64CrossRef
4.
Zurück zum Zitat Wormann B (2017) Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm 40(2):55–64 Wormann B (2017) Breast cancer: basics, screening, diagnostics and treatment. Med Monatsschr Pharm 40(2):55–64
5.
Zurück zum Zitat Patop IL, Wust S, Kadener S (2019) Past, present, and future of circRNAs. EMBO J 38(16):e100836CrossRef Patop IL, Wust S, Kadener S (2019) Past, present, and future of circRNAs. EMBO J 38(16):e100836CrossRef
6.
Zurück zum Zitat Xing C et al (2019) Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. Artif Cells Nanomed Biotechnol 47(1):3920–3928CrossRef Xing C et al (2019) Circular RNA ADAM9 facilitates the malignant behaviours of pancreatic cancer by sponging miR-217 and upregulating PRSS3 expression. Artif Cells Nanomed Biotechnol 47(1):3920–3928CrossRef
7.
Zurück zum Zitat Ameli-Mojarad M et al (2021) Circular RNA hsa_circ_0005046 and hsa_circ_0001791 may become diagnostic biomarkers for breast cancer early detection. J Oncol 2021:2303946CrossRef Ameli-Mojarad M et al (2021) Circular RNA hsa_circ_0005046 and hsa_circ_0001791 may become diagnostic biomarkers for breast cancer early detection. J Oncol 2021:2303946CrossRef
8.
Zurück zum Zitat Liu B, Li J, Cairns MJ (2014) Identifying miRNAs, targets and functions. Brief Bioinform 15(1):1–19CrossRef Liu B, Li J, Cairns MJ (2014) Identifying miRNAs, targets and functions. Brief Bioinform 15(1):1–19CrossRef
9.
Zurück zum Zitat Hu Y et al (2019) LINC01128 expedites cervical cancer progression by regulating miR-383-5p/SFN axis. BMC Cancer 19(1):1157CrossRef Hu Y et al (2019) LINC01128 expedites cervical cancer progression by regulating miR-383-5p/SFN axis. BMC Cancer 19(1):1157CrossRef
10.
Zurück zum Zitat Wei C, Gao JJ (2019) Downregulated miR-383-5p contributes to the proliferation and migration of gastric cancer cells and is associated with poor prognosis. PeerJ 7:e7882CrossRef Wei C, Gao JJ (2019) Downregulated miR-383-5p contributes to the proliferation and migration of gastric cancer cells and is associated with poor prognosis. PeerJ 7:e7882CrossRef
11.
Zurück zum Zitat Shao B et al (2020) RP11-284F21.9 promotes oral squamous cell carcinoma development via the miR-383-5p/MAL2 axis. J Oral Pathol Med 49(1):21–29CrossRef Shao B et al (2020) RP11-284F21.9 promotes oral squamous cell carcinoma development via the miR-383-5p/MAL2 axis. J Oral Pathol Med 49(1):21–29CrossRef
12.
Zurück zum Zitat Zhang Z et al (2020) MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer. J Cancer 11(13):3771–3782CrossRef Zhang Z et al (2020) MiR-891a-5p as a prognostic marker and therapeutic target for hormone receptor-positive breast cancer. J Cancer 11(13):3771–3782CrossRef
13.
Zurück zum Zitat Schluter K, Jockusch BM, Rothkegel M (1997) Profilins as regulators of actin dynamics. Biochim Biophys Acta 1359(2):97–109CrossRef Schluter K, Jockusch BM, Rothkegel M (1997) Profilins as regulators of actin dynamics. Biochim Biophys Acta 1359(2):97–109CrossRef
14.
Zurück zum Zitat Gareus R et al (2006) Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to dynamin 1. J Biol Chem 281(5):2803–2811CrossRef Gareus R et al (2006) Mouse profilin 2 regulates endocytosis and competes with SH3 ligand binding to dynamin 1. J Biol Chem 281(5):2803–2811CrossRef
15.
Zurück zum Zitat Cui XB et al (2016) PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma. J Transl Med 14(1):137CrossRef Cui XB et al (2016) PFN2, a novel marker of unfavorable prognosis, is a potential therapeutic target involved in esophageal squamous cell carcinoma. J Transl Med 14(1):137CrossRef
16.
Zurück zum Zitat Kim MJ et al (2015) Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells. Biosci Biotechnol Biochem 79(9):1438–1446CrossRef Kim MJ et al (2015) Profilin 2 promotes migration, invasion, and stemness of HT29 human colorectal cancer stem cells. Biosci Biotechnol Biochem 79(9):1438–1446CrossRef
17.
Zurück zum Zitat Patop IL, Kadener S (2018) circRNAs in cancer. Curr Opin Genet Dev 48:121–127CrossRef Patop IL, Kadener S (2018) circRNAs in cancer. Curr Opin Genet Dev 48:121–127CrossRef
18.
Zurück zum Zitat Tran AM et al (2020) A new world of biomarkers and therapeutics for female reproductive system and breast cancers: circular RNAs. Front Cell Dev Biol 8:50CrossRef Tran AM et al (2020) A new world of biomarkers and therapeutics for female reproductive system and breast cancers: circular RNAs. Front Cell Dev Biol 8:50CrossRef
19.
Zurück zum Zitat Abdollahzadeh R et al (2019) Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol 234(7):10080–10100CrossRef Abdollahzadeh R et al (2019) Competing endogenous RNA (ceRNA) cross talk and language in ceRNA regulatory networks: a new look at hallmarks of breast cancer. J Cell Physiol 234(7):10080–10100CrossRef
20.
Zurück zum Zitat Tian D et al (2020) Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p. Cell Death Dis 11(7):526CrossRef Tian D et al (2020) Circ-ADAM9 targeting PTEN and ATG7 promotes autophagy and apoptosis of diabetic endothelial progenitor cells by sponging mir-20a-5p. Cell Death Dis 11(7):526CrossRef
21.
Zurück zum Zitat Towler BP, Jones CI, Newbury SF (2015) Mechanisms of regulation of mature miRNAs. Biochem Soc Trans 43(6):1208–1214CrossRef Towler BP, Jones CI, Newbury SF (2015) Mechanisms of regulation of mature miRNAs. Biochem Soc Trans 43(6):1208–1214CrossRef
22.
Zurück zum Zitat Azarbarzin S et al (2020) MicroRNA-383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1. Life Sci 267:118939CrossRef Azarbarzin S et al (2020) MicroRNA-383-5p restrains the proliferation and migration of breast cancer cells and promotes apoptosis via inhibition of PD-L1. Life Sci 267:118939CrossRef
23.
Zurück zum Zitat Tian Y et al (2019) LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther 12:10569–10578CrossRef Tian Y et al (2019) LINC00096 promotes the proliferation and invasion by sponging miR-383-5p and regulating RBM3 expression in triple-negative breast cancer. Onco Targets Ther 12:10569–10578CrossRef
24.
Zurück zum Zitat Zhang J et al (2020) MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer. Cancer Biomark 27(4):423–432CrossRef Zhang J et al (2020) MicroRNA-383-5p acts as a potential prognostic biomarker and an inhibitor of tumor cell proliferation, migration, and invasion in breast cancer. Cancer Biomark 27(4):423–432CrossRef
26.
Zurück zum Zitat Jiang J et al (2019) Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27. Biomed Pharmacother 109:595–601CrossRef Jiang J et al (2019) Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27. Biomed Pharmacother 109:595–601CrossRef
27.
Zurück zum Zitat Zhao Y et al (2021) Circle RNA circABCB10 modulates PFN2 to promote breast cancer progression, as well as aggravate radioresistance through facilitating glycolytic metabolism via miR-223-3p. Cancer Biother Radiopharm 36(6):477–490 Zhao Y et al (2021) Circle RNA circABCB10 modulates PFN2 to promote breast cancer progression, as well as aggravate radioresistance through facilitating glycolytic metabolism via miR-223-3p. Cancer Biother Radiopharm 36(6):477–490
28.
Zurück zum Zitat Kim HS et al (2012) Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. BMC Genomics 13:348CrossRef Kim HS et al (2012) Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. BMC Genomics 13:348CrossRef
29.
Zurück zum Zitat Jiang M et al (2019) Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol 54(3):1043–1052 Jiang M et al (2019) Long noncoding RNA FOXD2AS1/miR1505p/PFN2 axis regulates breast cancer malignancy and tumorigenesis. Int J Oncol 54(3):1043–1052
30.
Zurück zum Zitat Ling Y et al (2021) Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells. Breast Cancer 28(2):368–378CrossRef Ling Y et al (2021) Profilin 2 (PFN2) promotes the proliferation, migration, invasion and epithelial-to-mesenchymal transition of triple negative breast cancer cells. Breast Cancer 28(2):368–378CrossRef
Metadaten
Titel
Knockdown of circ-ADAM9 inhibits malignant phenotype and enhances radiosensitivity in breast cancer cells via acting as a sponge for miR-383-5p
verfasst von
Penghui Song
Jianjun Wu
Jianbing Chen
Fang Wang
Jingmei Chen
Guanyu Wang
Publikationsdatum
07.10.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 1/2023
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-022-02006-0

Weitere Artikel der Ausgabe 1/2023

Strahlentherapie und Onkologie 1/2023 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.